Current Studies/Clinical Trials

Alzheimer’s Disease Neuroimaging Initiative – 3 (ADNI3)

Description: The overall goal is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD) from its earliest stages. Subjects will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection.

Study Length:  up to 5 years

Study Requirements:

  • 55-90 years of age
  • Cognitively normal; or have Mild Cognitive Impairment (MCI); or have been diagnosed with Alzheimer’s disease
  • A study partner who will accompany you to all study visits

Contact: MaryAnn Oakley at 412-692-2721 or


The Rhythm Experience and African Culture Trial (REACT!)

Description: REACT! Is an Alzheimer’s Association-funded study and will compare two activities, African Dance and an Education/Discussion Group, which might be beneficial for older African Americans aged 65-75.

Study Length:  Six months

Study Requirements: Africans Americans aged 65-75

Contact: Mariegold Wollam, Project coordinator at 412-302-6679 or visit:


Biogen (Emerge-Engage) Study

Description: This study will evaluate the efficacy and safety of an investigational drug, Aducanumab, for individuals with Early, Mild Alzheimer’s Disease or certain types of Mild Cognitive Impairment (MCI).  Study medication is administered by a once monthly infusion.

Study Length:  18 months

Study Requirements

  • 50-85 years of age
  • Diagnosis of mild Alzheimer’s disease or certain types of MCI
  • A study partner who will accompany the participant to all clinic visits


Carolyn Rickard at 412-692-2707 or or
MaryAnn Oakley at 412-692-2721 or


A4 Study

Description: The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease Trial, or A4 Study, is among a new generation of clinical trials being developed to test therapies that might prevent, or at least delay the onset of, Alzheimer’s disease in cognitively normal people who may be at risk as evidenced by a PET scan.

Study Length: 3 years

Study Requirements

  • 65 to 85 years of age
  • Normal thinking and memory abilities
  • Have a study partner with whom you have contact at least once a week who can answer questions about you once a year (contact may be in person or by phone)
  • Willing and able to receive IV infusions of the investigational drug (solanezumab) or a placebo every 4 weeks for 3 years

MaryAnn Oakley at 412-692-2721 or or
Thomas C Baumgartner, Jr 412-692-2716 or or
Sarah Goldberg 412-692-2730 or


Connectomes in Brain Aging

Description: This study will determine how different parts of the brain are connected and how these connections allow people to think, behave and feel. The study will involve 2-3 days of scanning and tests.  Some people will be asked to return after two years.

Study Length: 2-3 days and for some two years

Study Requirements

  • 50-89 years of age
  • Cognitively normal; or have Mild Cognitive Impairment (MCI); or have been diagnosed with Alzheimer’s disease.

MaryAnn Oakley at 412-692-2721 or or
Rebecca Roush 412-586-9860


Share This: